L-Carnitine Supplementation on Quality of Life and Other Health Measures

  • G. Mantovani
  • A. Macciò
  • C. Madeddu
  • G. Gramignano
Reference work entry


Chronic diseases often have a relapsing and remitting course with substantial impact on function and  quality of life (QL). For chronic illnesses where there is no cure, it is important to recognize that therapy really makes people feel better. Thus, survival per se is no longer perceived to be the only end point; the goal is to improve, restore, or preserve QL.

Quality of life and  supportive care are complementary concepts in the care of cancer patients. Nutritional support is a critical component of supportive care. However, both palliative and curative treatment of cancer should be accompanied by specific and patient-tailored nutritional intervention aiming at improving performance status and QL. Among the oral  nutritional supplements, L-carnitine with its nutritional, antioxidant, antimyopathic effects is one of the most promising. Several studies, carried out in cancer patients as well as in other chronic illnesses, demonstrated the ability of L-carnitine supplementation to in ameliorating QL, particularly  fatigue, and other symptoms, such as weight loss, pain, neuropathy and chemotherapy side effects, which in turn influence patient’s QL. In detail a recently published study of our group demonstrated the ability of L-carnitine oral supplementation (6g/day for 4 weeks) to induce increase of LBM, amelioration of fatigue and appetite. Several authors, in accordance to our results, showed that L-carnitine supplemented to cancer patients with fatigue and carnitine deficiency was able to ameliorate fatigue, sleep disorders and mood. Beside cancer patients, L-carnitine supplementation demonstrated to be able to improve quality of life in hemodialized patients and to ameliorate fatigue in celiac disease and multiple sclerosis patients as well as in elderly subjects. More clinical trials, however, are needed to identify those patients and diseases that may derive the greatest benefit from the supplementation with this agent. Indeed, while several studies have examined the role of L-carnitine supplementation in different comorbid conditions, very few have assessed its effect on QL.


Lean Body Mass Mental Fatigue Celiac Disease Patient Advanced Cancer Patient Carnitine Deficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


acquired immune deficiency syndrome


beck depression inventory


 cancer-related anorexia/cachexia syndrome


coenzyme A


chronic obstructive pulmonary disease


carnitine palmitoyltransferase


chronic renal failure


C-reactive protein


European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire


end-stage renal disease




lean body mass


multidimensional fatigue symptom inventory-short form


mini-mental state examination


medroxyprogesterone acetate


 oxidative stress


quality of life


reactive oxygen species


medical outcome study 36-item short form


tumor necrosis factor


visual analogue scales


World Health Organization


  1. Arrigoni-Martelli E, Caso V. (2001). Drugs Exp Clin Res. 27: 27–49.PubMedGoogle Scholar
  2. Beck A, Streer R, Brown G. (1996). Manual for the Beck Depression Inventory-II. Psychological Corporation, San Antonio, TX, USA.Google Scholar
  3. Beck SA, Groundwater P, Barton C, Tisdale MJ. (1990). Br J Cancer. 62: 822–825.PubMedCrossRefGoogle Scholar
  4. Boini S, Briancon S, Guillemin F, Galan P, Hercberg S. (2004). Health Qual Life Outcomes. 2: 4.PubMedCrossRefGoogle Scholar
  5. Brennan MF. (1977). Cancer Res. 37: 2359–2364.PubMedGoogle Scholar
  6. Bruera E. (1992). Oncology. 49(Suppl 2): 35–42.PubMedCrossRefGoogle Scholar
  7. Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA. (2006). J Nutr Biochem. 17: 73–88.PubMedCrossRefGoogle Scholar
  8. Caplan K. (1987). In: Aaronson NK, Beckmann J (eds.) The Quality of Life of Cancer Patients. Raven Press, New York, pp 1–9.Google Scholar
  9. Capra S, Ferguson M, Ried K. (2001). Nutrition. 17: 769–772.PubMedCrossRefGoogle Scholar
  10. Carr AJ, Thompson PW, Kirwan JR. (1996). Br J Rheumatol. 35: 275–281.PubMedCrossRefGoogle Scholar
  11. Ciacci C, Peluso G, Iannoni E, Siniscalchi M, Iovino P, Rispo A. et al. (2007). Dig Liver Dis. 39: 922–928.PubMedCrossRefGoogle Scholar
  12. Coates A. (1997). Support Care Cancer. 5: 435–438.PubMedCrossRefGoogle Scholar
  13. Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L. et al. (2004). Ann N Y Acad Sci. 1033: 168–176.PubMedCrossRefGoogle Scholar
  14. Cruciani RA, Dvorkin E, Homel P, Malamud S, Culliney B, Lapin J, et al. (2006). J Pain Symptom Manage. 32: 551–559.PubMedCrossRefGoogle Scholar
  15. Drewnowski A, Evans WJ. (2001). J Gerontol A Biol Sci Med Sci. 56(Spec No. 2): 89–94.PubMedGoogle Scholar
  16. Fitzpatrick R, Fletcher A, Gore S, Jones D, Spiegelhalter D, Cox D. (1992). BMJ. 305: 1074–1077.PubMedCrossRefGoogle Scholar
  17. Fletcher A, Gore S, Jones D, Fitzpatrick R, Spiegelhalter D, Cox D. (1992). BMJ. 305: 1145–1148.PubMedCrossRefGoogle Scholar
  18. Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L. et al. (2006). Nutrition. 22: 136–145.PubMedCrossRefGoogle Scholar
  19. Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E. et al. (2002). Br J Cancer. 86: 1854–1857.PubMedCrossRefGoogle Scholar
  20. Guarnieri G, Biolo G, Vinci P, Massolino B, Barazzoni R. (2007). J Ren Nutr. 17: 23–29.PubMedCrossRefGoogle Scholar
  21. He W, Lam TK, Obici S, Rossetti L. (2006). Nat Neurosci. 9: 227–233.PubMedCrossRefGoogle Scholar
  22. Heber D, Byerley LO, Chi J, Grosvenor M, Bergman RN, Coleman M. et al. (1986). Cancer. 58: 1867–1873.PubMedCrossRefGoogle Scholar
  23. Hoang BX, Graeme Shaw D, Pham P, Levine S. (2007). Med Hypotheses. 69: 262–272.PubMedCrossRefGoogle Scholar
  24. Katz MR, Kopek N, Waldron J, Devins GM, Tomlinson G. (2004). Psychooncology. 13: 269–280.PubMedCrossRefGoogle Scholar
  25. Laviano A, Meguid MM, Guijarro A, Muscaritoli M, Cascino A, Preziosa I. et al. (2006). Curr Opin Clin Nutr Metab Care. 9: 442–448.PubMedCrossRefGoogle Scholar
  26. Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. (2006). Mult Scler. 12: 321–324.PubMedCrossRefGoogle Scholar
  27. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G. et al. (1994). Cancer Res. 54: 5602–5606.PubMedGoogle Scholar
  28. Macciò A, Madeddu C, Mantovani G. (2006). In: Mantovani G (ed.) Cachexia and Wasting: A Modern Approach. Springer, New York, pp 195–203.CrossRefGoogle Scholar
  29. Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M. (2007). Am J Clin Nutr. 86: 1738–1744.PubMedGoogle Scholar
  30. Mantovani G, Maccio A, Madeddu C, Gramignano G, Serpe R, Massa E, et al. (2008). Nutrition. 24: 305–313.PubMedGoogle Scholar
  31. Mantovani G, Maccio A, Massa E, Madeddu C. (2001). Drugs. 61: 499–514.PubMedCrossRefGoogle Scholar
  32. Mantovani G, Madeddu C, Maccio A, Gramignano G, Lusso MR, Massa E. et al. (2004). Cancer Epidemiol Biomarkers Prev. 13: 1651–1659.PubMedGoogle Scholar
  33. Marin Caro MM, Laviano A, Pichard C. (2007). Clin Nutr. 26: 289–301.PubMedCrossRefGoogle Scholar
  34. Mintz M. (1995). J Child Neurol. 10(Suppl 2): S40–S44.PubMedGoogle Scholar
  35. Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C. et al. (2000). Oncology (Williston Park). 14: 151–161.Google Scholar
  36. Nelson K, Walsh D. (1991). Cancer Bull. 43: 403–406.Google Scholar
  37. NKF-K/DOQI. (2000). Clinical Practice Guidelines for Nutrition in chronic renal failure K/DOQI, National Kidney Foundation. Am J Kidney Dis. 2000; 35(6 Suppl 2): S1–140.Google Scholar
  38. Peltz G. (2002). Nutr J. 1: 1.PubMedCrossRefGoogle Scholar
  39. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL. et al. (2003). Science. 300: 1140–1142.PubMedCrossRefGoogle Scholar
  40. Rathod R, Baig MS, Khandelwal PN, Kulkarni SG, Gade PR, Siddiqui S. (2006). Indian J Med Sci. 60: 143–153.PubMedCrossRefGoogle Scholar
  41. Rebouche C. (1999). In: Shike M, Ross A (eds.) Nutrition in Health and Disease, 9th ed. Williams & Wilkins, Baltimore, pp. 505–512.Google Scholar
  42. Reda E, D’Iddio S, Nicolai R, Benatti P, Calvani M. (2003). Acta Diabetol. 40(Suppl 1): S106–S113.PubMedCrossRefGoogle Scholar
  43. Reuter SE, Faull RJ, Evans AM. (2008). Nephrology (Carlton). 13: 3–16.Google Scholar
  44. Stein KD, Jacobsen PB, Blanchard CM, Thors C. (2004). J Pain Symptom Manage. 27: 14–23.PubMedCrossRefGoogle Scholar
  45. Steiber AL, Davis AT, Spry L, Strong J, Buss ML, Ratkiewicz MM, et al. (2006). JPEN J Parenter Enteral Nutr. 30: 10–15.PubMedCrossRefGoogle Scholar
  46. The World Health Organization. (1995). Soc Sci Med. 41: 1403–1409.CrossRefGoogle Scholar
  47. The World Health Organization. (1998). Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med. 46: 1569–1585.CrossRefGoogle Scholar
  48. Tisdale MJ. (2005). Physiology (Bethesda). 20: 340–348.Google Scholar
  49. Ware JE Jr., Brook RH, Davies AR, Lohr KN. (1981). Am J Public Health. 71: 620–625.PubMedCrossRefGoogle Scholar
  50. Ware JE Jr., Sherbourne CD. (1992). Med Care. 30: 473–483.PubMedCrossRefGoogle Scholar
  51. Winningham ML, Nail LM, Burke MB, Brophy L, Cimprich B, Jones LS. et al. (1994). Oncol Nurs Forum. 21: 23–36.PubMedGoogle Scholar
  52. Winter S, Jue K, Prochazka J, Francis P, Hamilton W, Linn L. et al. (1995). J Child Neurol. 10(Suppl 2): S45–S51.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • G. Mantovani
  • A. Macciò
  • C. Madeddu
  • G. Gramignano

There are no affiliations available

Personalised recommendations